Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia

被引：117

作者：

Macdougall, Iain C.

Eckardt, Kai-Uwe

机构：

[1] Kings Coll Hosp London, Dept Renal Med, London SE5 9RS, England

[2] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Erlangen, Germany

来源：

LANCET | 2006年 / 368卷 / 9539期

关键词：

D O I：

10.1016/S0140-6736(06)69120-4

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

As with many other therapeutic areas in modern-day medicine, scientific advances in drug development (using such techniques as recombinant DNA technology, site-directed mutagenesis, pegylation of molecules, peptide library screening, and gene transfer) have resulted in the development of potential new agents and strategies for stimulating erythropoiesis. These advances are of possible benefit in treating anaemia due to various causes, including chronic renal failure. Several new treatments will soon become clinically available, while others are at present at an early stage of development but are nevertheless of scientific interest. We review these new therapeutic strategies, and discuss at what stage some of the newer products are in relation to their clinical development programme.

引用

页码：947 / 953

页数：7

共 61 条

[1]

The critical role of Src homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients [J].

Akagi, S ;

Ichikawa, H ;

Okada, T ;

Sarai, A ;

Sugimoto, T ;

Morimoto, H ;

Kihara, T ;

Yano, A ;

Nakao, K ;

Nagake, Y ;

Wada, J ;

Makino, H .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (12) :3215-3224

[2]

ALEXANIAN R, 1967, J LAB CLIN MED, V70, P777

[3]

[Anonymous], J AM SOC NEPHROLOGY

[4]

Pure red-cell aplasia and epoetin therapy [J].

Bennett, CL ;

Luminari, S ;

Nissenson, AR ;

Tallman, MS ;

Klinge, SA ;

McWilliams, N ;

McKoy, JM ;

Kim, B ;

Lyons, EA ;

Trifilio, SM ;

Raisch, DW ;

Evens, AM ;

Kuzel, TM ;

Schumock, GT ;

Belknap, SM ;

Locatelli, F ;

Rossert, J ;

Casadevall, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (14) :1403-1408

[5]

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].

Besarab, A ;

Bolton, WK ;

Browne, JK ;

Egrie, JC ;

Nissenson, AR ;

Okamoto, DM ;

Schwab, SJ ;

Goodkin, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590

[6]

Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy [J].

Binley, K ;

Askham, Z ;

Iqball, S ;

Spearman, H ;

Martin, L ;

de Alwis, M ;

Thrasher, AJ ;

Ali, RR ;

Maxwell, PH ;

Kingsman, S ;

Naylor, S .

BLOOD, 2002, 100 (07) :2406-2413

[7]

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes [J].

Boven, K ;

Stryker, S ;

Knight, J ;

Thomas, A ;

van Regenmortel, M ;

Kemeny, DM ;

Power, D ;

Rossert, J ;

Casadevall, NE .

KIDNEY INTERNATIONAL, 2005, 67 (06) :2346-2353

[8]

CARO J, 1979, J LAB CLIN MED, V93, P449

[9]

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].

Casadevall, N ;

Nataf, J ;

Viron, B ;

Kolta, A ;

Kiladjian, J ;

Martin-Dupont, P ;

Michaud, P ;

Papo, T ;

Ugo, V ;

Teyssandier, I ;

Varet, B ;

Mayeux, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475

[10]

Pleiotropic renal actions of erythropoietin [J].

Chatterjee, PK .

LANCET, 2005, 365 (9474) :1890-1892

← 1 2 3 4 5 6 7 →